GLP-1 Receptors Glucagon-like peptide (GLP-1) receptor agonists are used to treat diabetes by activating GLP-1 receptors in the pancreas, which leads to enhanced insulin release and reduced glucagon release responses that are glucose-dependent, with a consequent low risk for hypoglycemia
Yes, there is no contraindication to using GLP-1 medications in patients with Hashimoto's thyroiditis
More serious but rare adverse effects include pancreatitis, gallbladder problems, and changes in vision
for individuals 65 and older
As the area postrema lacks the blood-brain barrier, it serves as a key site for peripheral GLP-1 to activate central autonomic regulatory sites
Their high water content also helps keep you hydrated, making them a refreshing and versatile option